NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) state that pertuzumab, trastuzumab, and hyaluronidase-zzxf injection for subcutaneous use (PHESGO) may be substituted anywhere that IV pertuzumab (PERJETA) + trastuzumab are given as part of systemic therapy for HER2+ breast cancer.†3

PHESGO has different dosing and administration instructions compared to the intravenous products.

PHESGO is FDA approved for all of the same HER2+ breast cancer indications as PERJETA.1,2

Learn more about administering PHESGO

This video will give you step-by-step preparation and administration instructions, storage and product information, and Important Safety Information.

To learn more about administering PHESGO, or to schedule an educational in-service contact us at

Video Transcript

Genentech Access Solutions offers a range of access and reimbursement support for your patients and practice.